Fresh positive news from promising vaccine trials offset concerns around the stubbornly high global infection rate and tighter restrictions.
Sentiment across markets was mixed, caught between fears that Europe heads for a double-dip recession and promising vaccine news.
Risk appetite in currency markets eased, as rising COVID-19 hospitalisations in Europe and the United States tempered euphoria about a possible vaccine.
Investors’ sentiment bounces back and forth as U.S. coronavirus infections surged and they weighed the timeline of the roll-out of an effective vaccine.
There are still several obstacles to clear before a vaccine can be distributed so the vaccine optimism momentum is starting to fade.